Lingyi Biotech Co., Ltd.
Clinical trials sponsored by Lingyi Biotech Co., Ltd., explained in plain language.
-
One-Time brain injection targets genetic form of Parkinson's
Disease control Not yet recruitingThis early-stage trial tests a single injection of a gene therapy called LY-N001, given directly into the brain fluid of people aged 30 to 70 with moderate-to-advanced Parkinson's disease who carry a GBA1 gene mutation. The main goal is to check safety and side effects, but resea…
Phase: EARLY_PHASE1 • Sponsor: Lingyi Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Gene therapy could free Wilson's patients from daily pills
Disease control Not yet recruitingThis early-stage trial tests a single-dose gene therapy called LY-M003 in 18 adults with Wilson's disease, a genetic condition that causes copper buildup. The goal is to see if it's safe and can reduce or eliminate the need for standard daily medications. Participants receive one…
Phase: PHASE1, PHASE2 • Sponsor: Lingyi Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC